Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 116 publications
TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.
Journal: Future oncology (London, England)
Published: May 16, 2026
Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab.
Journal: European urology oncology
Published: March 20, 2026
Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder Cancer.
Journal: Clinical genitourinary cancer
Published: December 17, 2025
Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer.
Journal: JCO precision oncology
Published: December 05, 2025
Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: December 04, 2025
Real-World Outcomes of Patients With Baseline Neuropathy and/or Diabetes Mellitus Receiving Enfortumab Vedotin-Based Regimens for Advanced Urothelial Carcinoma in the UNITE Database.
Journal: Clinical genitourinary cancer
Published: December 02, 2025
Association between smoking, tumor genetics, and outcomes in men with metastatic prostate cancer.
Journal: Prostate cancer and prostatic diseases
Published: December 02, 2025
Correlation of lymphocytic infiltration and degree of pleomorphism with tumor mutation burden in high-grade urothelial carcinoma.
Journal: Human pathology
Published: October 21, 2025
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.
Journal: CA: a cancer journal for clinicians
Published: September 15, 2025
Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists.
Journal: Clinical genitourinary cancer
Published: July 16, 2025
Genomic alterations and associated outcomes in patients with PSMA-positive metastatic castration-resistant prostate cancer treated with 177Lu-PSMA-617.
Journal: The oncologist
Published: June 27, 2025
Efficacy of erdafitinib before or after enfortumab vedotin in FGFR3-altered advanced urothelial cancer: analysis of the UNITE collaborative study.
Journal: The oncologist
Published: June 09, 2025
Last Updated: 09/26/2026